中年认知活动对与tau相关的认知障碍的适度
Kang Ko1,2, Dahyun Yi3, Min Soo Byun1,4
1Department of Psychiatry, Seoul National University College of Medicine, Seoul, Republic of Korea.
Alzheimer's & dementia : the journal of the Alzheimer's Association
|February 24, 2025
概括
中年认知活动 (CA) 尽管有tau病理,但可能会增强认知功能,但矛盾的是,在轻度认知障碍患者中加速衰退. 晚年CA没有表现出这种缓和作用.
科学领域:
- 神经科学是一个神经科学.
- 老年学是一门学科.
- 认知心理学 认知心理学
背景情况:
- 病理是神经退行性疾病的标志.
- 认知活动 (CA) 可能会影响认知性.
- 中年和晚年CA,tau病理和认知轨迹之间的相互作用尚未完全理解.
研究的目的:
- 研究中年和晚年认知活动 (CA) 对病理与认知表现和下降之间的关系的缓和效应.
- 为了检查CA在tau病理的存在下如何影响认知轨迹.
主要方法:
- 评估了来自韩国队列的89名非痴呆症老年人.
- 综合评估包括基线CA评估和tau神经成像.
- 迷你精神状态检查 (MMSE) 在基线和2年后续进行.
主要成果:
- 更长的中年CA与特定水平的tau病理学MMSE得分更高有关.
- 较高的中年CA与较快的相关的MMSE下降有关,特别是在轻度认知障碍患者中.
- 晚年CA并没有缓解tau和MMSE得分之间的关联或随时间的变化.
结论:
- 中年CA通常支持面对tau病理的更好的认知表现.
- 矛盾的是,中年CA的增加可能会加速与tau相关的认知衰退,而这些人已经存在认知障碍.
- 晚年CA似乎没有缓解tau病理对认知的影响.
更多相关视频
06:22A Pilot Study on the Repetitive Transcranial Magnetic Stimulation of Aβ and Tau Levels in Rhesus Monkey Cerebrospinal Fluid
Published on: September 3, 2021
3.6K
10:13Assessment of Age-related Changes in Cognitive Functions Using EmoCogMeter, a Novel Tablet-computer Based Approach
Published on: February 14, 2014
13.6K
相关概念视频
Cognitive Development During Adulthood
45
Cognitive development continues throughout adulthood, undergoing significant shifts across early, middle, and late stages. Individual transition occurs from adolescent idealism to pragmatic and adaptable thinking in early adulthood. During this period, individuals learn to integrate personal beliefs with the recognition that other perspectives are equally valid. Exposure to the complexities of modern society, diverse experiences, and higher education contribute to this adaptive thought process,...
45
Alzheimer's Disease: Treatment
149
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
149
Alzheimer's Disease: Overview
425
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
425
Cognitive Enhancers: Cholinesterase Inhibitors and NMDA Receptor Antagonists
95
Cognitive enhancers, also known as "smart drugs," are substances used to enhance memory, mental alertness, and concentration. These can be natural or synthetic and improve cognition in conditions like Alzheimer's disease (AD) and other neurodegenerative diseases. Some common examples include caffeine, amphetamines, methylphenidate, modafinil, arecoline, donepezil, vortioxetine, and piracetam. These enhancers work on the principle of synaptic plasticity and altered circuit function.
95
Dementia
88
Dementia is a collective term for cognitive disorders primarily affecting memory, thinking, and reasoning. It is not a specific disease but a syndrome, with Alzheimer's disease being the most common cause, accounting for approximately 60-80% of cases. Other types include vascular dementia, Lewy body dementia, and frontotemporal dementia. Dementia affects millions worldwide, particularly older adults, though it is not a normal part of aging.
The progression of dementia is generally gradual....
The progression of dementia is generally gradual....
88
